PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Both yoy net incomes decline, with TRAW at -27.95%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-9.94%
Negative yoy D&A while TRAW is 17.50%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-368.86%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth well above TRAW's 23.42%. Michael Burry would flag major dilution risk vs. competitor’s approach.
55.40%
Less working capital growth vs. TRAW's 130.36%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
AP growth well above TRAW's 41.29%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-12.95%
Negative yoy usage while TRAW is 151.43%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
200.11%
Well above TRAW's 67.69%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-85.28%
Negative yoy CFO while TRAW is 5.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
80.16%
CapEx growth well above TRAW's 23.40%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
Lower net investing outflow yoy vs. TRAW's 10661.70%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
54.75%
Debt repayment growth of 54.75% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-0.41%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.